OBJECTIVE: To assess trends during 2009-2013 in antiretroviral therapy (ART) prescription and viral suppression among adults receiving HIV clinical care in the United States. DESIGN: We used data from the Medical Monitoring Project, a surveillance system producing national estimates of characteristics of HIV-infected adults receiving clinical care in the United States. METHODS: We estimated weighted proportions of persons receiving HIV medical care who were prescribed ART and achieved HIV viral suppression (<200 copies/ml) at both last test and at all tests in the previous 12 months during 2009-2013. We assessed trends overall and by gender, age, race/ethnicity, and sexual behavior/orientation. RESULTS: ART prescription and viral suppression increased significantly during 2009-2013, overall and in subgroups. ART prescription increased from 89 to 94% (P for trend <0.01). Viral suppression at last measurement increased from 72 to 80% (P for trend <0.01). The largest increases were among 18-29 year olds (56-68%), 30-39 year olds (62-75%), and non-Hispanic blacks (64-76%). Sustained viral suppression increased from 58 to 68% (P for trend <0.01). The largest increases were among 18-29 year olds (32-51%), 30-39 year olds (47-63%), and non-Hispanic blacks (49-61%). CONCLUSION: Adults receiving HIV medical care are increasingly likely to be prescribed ART and achieve viral suppression. Recent efforts to promote early antiretroviral therapy use may have contributed to these increases, bringing us closer to realizing key goals of the National HIV/AIDS Strategy.
OBJECTIVE: To assess trends during 2009-2013 in antiretroviral therapy (ART) prescription and viral suppression among adults receiving HIV clinical care in the United States. DESIGN: We used data from the Medical Monitoring Project, a surveillance system producing national estimates of characteristics of HIV-infected adults receiving clinical care in the United States. METHODS: We estimated weighted proportions of persons receiving HIV medical care who were prescribed ART and achieved HIV viral suppression (<200 copies/ml) at both last test and at all tests in the previous 12 months during 2009-2013. We assessed trends overall and by gender, age, race/ethnicity, and sexual behavior/orientation. RESULTS: ART prescription and viral suppression increased significantly during 2009-2013, overall and in subgroups. ART prescription increased from 89 to 94% (P for trend <0.01). Viral suppression at last measurement increased from 72 to 80% (P for trend <0.01). The largest increases were among 18-29 year olds (56-68%), 30-39 year olds (62-75%), and non-Hispanic blacks (64-76%). Sustained viral suppression increased from 58 to 68% (P for trend <0.01). The largest increases were among 18-29 year olds (32-51%), 30-39 year olds (47-63%), and non-Hispanic blacks (49-61%). CONCLUSION: Adults receiving HIV medical care are increasingly likely to be prescribed ART and achieve viral suppression. Recent efforts to promote early antiretroviral therapy use may have contributed to these increases, bringing us closer to realizing key goals of the National HIV/AIDS Strategy.
Authors: Julia C Dombrowski; Susan E Buskin; Amy Bennett; Hanne Thiede; Matthew R Golden Journal: J Acquir Immune Defic Syndr Date: 2014-11-01 Impact factor: 3.731
Authors: Beatriz Grinsztejn; Mina C Hosseinipour; Heather J Ribaudo; Susan Swindells; Joseph Eron; Ying Q Chen; Lei Wang; San-San Ou; Maija Anderson; Marybeth McCauley; Theresa Gamble; Nagalingeshwaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Jose H S Pilotto; Sheela V Godbole; Suwat Chariyalertsak; Marineide Gonçalves de Melo; Kenneth H Mayer; Susan H Eshleman; Estelle Piwowar-Manning; Joseph Makhema; Lisa A Mills; Ravindre Panchia; Ian Sanne; Joel Gallant; Irving Hoffman; Taha E Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Diane Havlir; Myron S Cohen Journal: Lancet Infect Dis Date: 2014-03-04 Impact factor: 25.071
Authors: Alan E Greenberg; David W Purcell; Christopher M Gordon; Rebecca J Barasky; Carlos del Rio Journal: J Acquir Immune Defic Syndr Date: 2015-05-01 Impact factor: 3.731
Authors: Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton Journal: N Engl J Med Date: 2015-07-20 Impact factor: 91.245
Authors: Tuan Le; Edwina J Wright; Davey M Smith; Weijing He; Gabriel Catano; Jason F Okulicz; Jason A Young; Robert A Clark; Douglas D Richman; Susan J Little; Sunil K Ahuja Journal: N Engl J Med Date: 2013-01-17 Impact factor: 91.245
Authors: Peter Rebeiro; Keri N Althoff; Kate Buchacz; John Gill; Michael Horberg; Hartmut Krentz; Richard Moore; Timothy R Sterling; John T Brooks; Kelly A Gebo; Robert Hogg; Marina Klein; Jeffrey Martin; Michael Mugavero; Sean Rourke; Michael J Silverberg; Jennifer Thorne; Stephen J Gange Journal: J Acquir Immune Defic Syndr Date: 2013-03-01 Impact factor: 3.731
Authors: Ellen M Tedaldi; James T Richardson; Rachel Debes; Benjamin Young; Joan S Chmiel; Marcus D Durham; John T Brooks; Kate Buchacz Journal: J Int Assoc Provid AIDS Care Date: 2014-02-03
Authors: Hasina Samji; Angela Cescon; Robert S Hogg; Sharada P Modur; Keri N Althoff; Kate Buchacz; Ann N Burchell; Mardge Cohen; Kelly A Gebo; M John Gill; Amy Justice; Gregory Kirk; Marina B Klein; P Todd Korthuis; Jeff Martin; Sonia Napravnik; Sean B Rourke; Timothy R Sterling; Michael J Silverberg; Stephen Deeks; Lisa P Jacobson; Ronald J Bosch; Mari M Kitahata; James J Goedert; Richard Moore; Stephen J Gange Journal: PLoS One Date: 2013-12-18 Impact factor: 3.240
Authors: Kate Buchacz; Emma L Frazier; H Irene Hall; Rachel Hart; Ping Huang; Dana Franklin; Xiaohong Hu; Frank J Palella; Joan S Chmiel; Richard M Novak; Kathy Wood; Bienvenido Yangco; Carl Armon; John T Brooks; Jacek Skarbinski Journal: Open AIDS J Date: 2015-12-07
Authors: Kate Buchacz; Carl Armon; Ellen Tedaldi; Frank J Palella; Richard M Novak; Douglas Ward; Rachel Hart; Marcus D Durham; John T Brooks Journal: AIDS Res Hum Retroviruses Date: 2018-02-13 Impact factor: 2.205
Authors: Irene S Yoon; Martin J Downing; Richard Teran; Mary Ann Chiasson; Steven T Houang; Jeffrey T Parsons; Sabina Hirshfield Journal: AIDS Care Date: 2017-12-19
Authors: Michael J Stirratt; Gary Marks; Christine O'Daniels; Edward R Cachay; Meg Sullivan; Michael J Mugavero; Shireesha Dhanireddy; Allan E Rodriguez; Thomas P Giordano Journal: Sex Transm Infect Date: 2017-11-02 Impact factor: 3.519
Authors: Heather Bradley; Keri N Althoff; Kate Buchacz; John T Brooks; M John Gill; Michael A Horberg; Mari M Kitahata; Vincent Marconi; Kenneth H Mayer; Angel Mayor; Richard Moore; Michael Mugavero; Sonia Napravnik; Gabriela Paz-Bailey; Joseph Prejean; Peter F Rebeiro; Christopher T Rentsch; R Luke Shouse; Michael J Silverberg; Patrick S Sullivan; Jennifer E Thorne; Baligh Yehia; Eli S Rosenberg Journal: Ann Epidemiol Date: 2018-11-22 Impact factor: 3.797
Authors: Peter Francis Rebeiro; Kelsey Sunderland Ivey; Kaylin Smith Craig; Todd Hulgan; Moises Arturo Huaman; Robertson Nash; Stephen Raffanti; Kehinde Amen Equakun; Anna Kristine Person Journal: J Int Assoc Provid AIDS Care Date: 2017-05-31
Authors: Anne M Neilan; Richard Dunville; M Cheryl Bañez Ocfemia; Joshua A Salomon; Jordan A Francke; Alexander J B Bulteel; Li Yan Wang; Katherine K Hsu; Elizabeth A DiNenno; Rochelle P Walensky; Robert A Parker; Kenneth A Freedberg; Andrea L Ciaranello Journal: J Adolesc Health Date: 2018-01 Impact factor: 5.012